AUG 14, 2026 · JOURNAL ARTICLE
Potential prognostic value of the free T3/T4 ratio in HR+/HER2 − metastatic breast cancer treated with CDK4/6 inhibitors
BMC Cancer
Single-centre retrospective cohort study with clinical endpoints (PFS, OS) in a defined population, showing statistically significant associations, but limited by retrospective design, lack of mechanistic validation, and absence of external validation.
Reported
Sample size162
Progression-free survival — media…9.7 months
Progression-free survival — media…6.9 months